Outcome of Board Meeting_Change in designation of Senior Management Personnel
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Biocon Limited's Board meeting on May 7, 2026 approved multiple key decisions. The company approved audited financial results for Q4 and FY26, recommended a final dividend of Rs. 0.50 per share (10%) for FY26, and appointed S.R. Batliboi & Associates LLP as new statutory auditors replacing B S R & Co. LLP for 5 years. Two senior executives were formally designated as Senior Management Personnel: Dr. Anuj Goel as Chief Development Officer and Mr. Susheel Umesh as Chief Commercial Officer - Emerging Markets, both effective immediately. The board also approved appointment of 5 new independent directors and 1 non-executive director, along with acquiring the remaining ~2% stake in Biocon Biologics Limited (BBL) for Rs. 330.73 Crores through a share swap of 87.92 lakh equity shares at Rs. 376.16 per share.
This is a positive development signaling management succession planning and full integration of BBL as a wholly-owned subsidiary. The share swap will dilute existing shareholders by ~87.92 lakh shares but consolidates the high-growth biosimilars business.